Critical Authentication Bypass & Hard‑coded Credentials in Mira Hormone Monitor Firmware & Android App (CVE‑2026‑66875, CVE‑2026‑66098, CVE‑2026‑67558, CVE‑2026‑67568, CVE‑2026‑68067, CVE‑2026‑66340, CVE‑2026‑64934, CVE‑2026‑66832)
What It Is — A cluster of eight high‑severity flaws discovered in the Mira Hormone Monitor firmware (v1.7.1.47) and the companion Mira Android app (v4.5.15.4). The bugs include missing authentication for critical functions, authentication bypass by spoofing, hard‑coded credentials, weak authentication, and reliance on untrusted input.
Exploitability — CVSS v3.1 base score 9.8 (Critical). Public advisories list remote, unauthenticated exploitation paths; proof‑of‑concept code has been shared in underground forums. No vendor patch is yet available.
Affected Products —
- Mira Hormone Monitor firmware 1.7.1.47 (all units shipped worldwide)
- Mira Android App 4.5.15.4 (Android 10+)
Why It Matters for Compliance & Audit Readiness
- Access‑control coverage – SOC 2 CC6.1 requires documented, enforced authentication for all privileged functions; these flaws demonstrate a gap that auditors will flag.
- Audit‑ready evidence – Continuous monitoring of device‑level controls (e.g., credential rotation, session‑token handling) provides the evidence needed to prove “least‑privilege” enforcement.
- Data‑privacy impact – Unauthorized read/write of health profiles triggers HIPAA‑related controls (CC7.1) and can be a red flag in a SOC 2 audit of a healthcare SaaS provider.
Recommended Actions
- Map the defects to SOC 2 CC6.1/CC6.2 controls and record the gap in your control inventory.
- Implement compensating controls (network segmentation, MFA for device management consoles, and strict API gateway validation) while awaiting a vendor patch.
- Capture continuous evidence of the compensating controls (e.g., firewall logs, MFA logs) to satisfy audit‑readiness reviewers.
- Engage the vendor for an expedited firmware/app patch and obtain a signed remediation timeline for audit documentation.
Source: CISA Advisory ICSMA‑26‑223‑01